Latest Event Updates
A new report published by Allied Market Research, titled, “Ultrasound Devices Market – Global Opportunity Analysis and Industry Forecast, 2014 – 2022”, projects that the global ultrasound market would reach $10,476 million by 2022. Diagnostic ultrasound system would continue to be the highest revenue-generating segment throughout the forecast period. Europe accounted for almost one-third of the market share in 2015, and is expected to dominate the overall market during the study period.
The major factors boosting the market growth include technological advancements (such as advent of 3D and 4D ultrasound that provides detailed information about a known abnormality from different angles), rising incidence of chronic diseases, and increasing geriatric population worldwide. The rising number of application areas of ultrasound coupled with increasing adoption of ultrasound systems in obstetrics and gynaecology field, is set to boost the growth of the ultrasound market worldwide. Cost effectiveness, safety, high accessibility, and clinical value in preliminary diagnosis are strengthening the technologies value proposition in technological advancements in the ultrasound market. In addition, increase in number of diagnostic imaging procedures, and rising awareness for early diagnosis of clinical disorders are anticipated to further drive the demand for ultrasound devices. However, dearth of skilled and experienced sonographers and technological limitations of ultrasound systems are some of the factors restricting the market growth.
Diagnostic ultrasound devices such as 2D ultrasound, 3D & 4D ultrasound, and Doppler devices have given rise to new applications (such as biopsies and image-guiding interventions) across different clinical specialties. The growing demand for both ultra-portable and portable diagnostic ultrasound systems in diagnostic and image guidance area at points-of-care have further boosted the market growth. The advent of portability in ultrasound has built a strong path for the increased demand of these devices for point-of-care applications such as emergency medicine, anesthesiology, musculoskeletal, and critical care medicine. The trolley/cart-based ultrasound devices segment accounted for the major market share of the total ultrasound market in 2015, whereas, the compact/handheld ultrasound devices segment is expected to grow at a higher CAGR during the forecast period
Geographically, the European region accounted for the majority share in the overall ultrasound market in 2015, and is expected to maintain this lead throughout the forecast period. The growth in the ultrasound market is attributed to the increased adoption of ultrasound for diagnosis, increased procedure volumes resulting from rapidly aging population, and increased prevalence of chronic diseases. However, regulatory framework concerns and dearth of experienced and skilled sonographers in various countries in Europe are expected to hamper the market growth. In addition, the growing momentum of HIFU in European countries for the treatment of prostate cancer is further set to drive the ultrasound market. Asia-Pacific is projected to be the fastest growing region throughout the analysis period. This is mainly due to the improving healthcare infrastructure and healthcare expenditures in the emerging markets (such as India and China) to overcome the unmet medical needs in these countries. Technological advancements for cost-effective devices in these nations offers a lucrative opportunity for the growth of the ultrasound devices market.
Key Findings of Ultrasound Devices Market:
In the year 2015, 2D imaging systems was the leading segment, accounting for almost half of the overall market revenue, and is projected to grow at a CAGR of 3.3% during the forecast period.
HIFU segment is expected to grow at a remarkable CAGR of 22.5%, owing to the non-invasive nature and high accuracy of technology for the treatment of prostate cancer.
Asia-Pacific accounted for about one-third share of the global ultrasound market in 2015.
The obstetrics/gynecology segment is projected to surpass the ultrasound market for radiology/general imaging during the forecast period.
China and Japan are the major shareholders in the Asia-Pacific region, jointly accounting for about two-thirds share of the regions ultrasound market.
The key players in the ultrasound market are highly focused on expanding their business operations in the fast-growing emerging countries and new product launches as a preferred strategy. The companies profiled in this report include Analogic Corporation, Esaote SpA, Fujifilm Corporation, General Electric Company, Hitachi, Ltd., Koninklijke Philips N.V., Mindray Medical International Limited, Samsung Medison Co. Ltd, Siemens AG, and Toshiba Corporation.
Neuromodulation devices to treat Parkinson’s and other chronic diseases show positive results in patients
Neuromodulation device market has seen a steady growth in the last decade. The market size has grown owing to the wide array of medical applications in chronic pain, epilepsy, tremor, and migraine. The rise in geriatric population worldwide has also contributed to the expansion of the neuromodulation device market. The technology has been adopted on a larger scale in the developed regions, such as U.S., Canada, and Europe. Technological advancements and developments in the field of neuromodulation in the aforementioned regions has led to a higher adoption rate. Developing countries such as China and India are gradually embracing new innovations in the field of neuromodulation. The true potential of neuromodulation devices has not been recognized yet as the technology is still at a nascent stage. A report that provides valuable insight on the neuromodulation devices market such as market share, size, and growth has been published by Allied Market Research recently.
Read more details at: https://www.alliedmarketresearch.com/neurostimulation-devices-market
Neuromodulation devices for Parkinson’s disease
It is estimated that around 10 million people suffer from Parkinson’s disease worldwide. The cost to curb the disease is high and often it becomes impossible for patients to afford the required treatment. Till date, there is no real cure to treat Parkinson’s. However, major breakthroughs in the medical field have shown promising results and soon we might see a full proof treatment that cures the disease completely.
The symptoms include slow movements, tremors, cerebral impairment, and rigidity. Neurostimulators are implanted into the brain using the brain stimulation technique. The surgically implanted device helps to deal with tremors and has the potential to eliminate the same altogether. It was first introduced in 1987 but received FDA approval a decade later. Deep brain stimulation has been successful for multiple patients. However, there have been cases that have reported a few side effects such as depression, apathy, euphoria, and hallucinations. There is also a risk of bleeding when a foreign object is inserted in the body. At times, the body rejects entry of foreign objects which is another obstacle that scientists and researchers are working on.
New medications and developments have shown promising results according to Dr. Peter Schmidt, chief mission officer, National Parkinson Foundation. The new medications are still under the testing phase and would require to undergo a few more tests. Nilotinib and Isradipine are a couple of drugs that have delivered positive results and hold a promising future.
In 2011, DaTscan, a radiopharmaceutical agent got the approval from the FDA. It is injected into the patient’s veins and detects the presence of dopamine in the brain. Dopamine is a neurotransmitter that helps the body to function smoothly. The risk of being infected by Parkinson’s increases when the dopamine-producing neurons in the brain start to reduce. According to Dr. Badih Adada, director of Neurology Center at Cleveland Clinic Florida, the test was available only in the United States and Europe and is a commendable advance made in the right direction. The rise in several such inventions and advancements is further driving the neuromodulation device market.
Neuromodulation system to treat over active bladder
There were not many advances made as far as urinary and fecal dysfunction is concerned. Researchers were looking for a ray of hope to deal with the problem. There were a few promising signs but nothing ever materialized in a way so as to help the patients.
Axonics Modulation Technologies, Inc., were the first developers of the rechargeable implantable Sacral Neuromodulation (SNM) System. In June 2016, the company announced that its first patients were successfully implanted in London and the Netherlands. Professor van Kerrebroeck threw some light on the topic and revealed that the small and compact rechargeable SNM System is a big step forward for the patients suffering from the problem and seeking a long-term solution for the same. OAB has affected around 85 million people in U.S and Europe. Sacral Neuromodulation is an effective and reliable treatment that is popular in the developed regions. Around 200,000 patients have been treated with the therapy with positive results. It is the only OAB treatment that has gained importance compared to standard drug therapy.
Over the past few years, medical implants have facilitated medical professionals to treat a wide variety of clinical conditions related to orthopaedics, cardiovascular, ophthalmology, cosmetics, and neurostimulation. Orthopaedic implant and neurostimulator segments are expected to offer huge market potential to the key players.
The key players in the medical implants industry employ novel concepts and ideas to improvise manufacturing techniques and the current set of products, so as to gain a competitive edge in the market. Therefore, these players have adopted product launches as their key developmental strategy in order to meet the increasing demands of end users. Further, the companies have also adopted other strategies such as strategic acquisitions, mergers, expansions, and collaborations.
Read more about medical implant at: https://www.alliedmarketresearch.com/medical-implants-market
Each segment of medical implants market is almost consolidated in nature and is governed by different key players in the industry. For instance, Abbott Laboratories, Boston Scientific and Medtronic dominate stents segment. Similarly, DePuy Synthes, Zimmer Biomet and Smith & Nephew are the leading players in the orthopaedics market. DePuy Synthes leads the overall orthopaedics market with the largest and most comprehensive product portfolio of orthopaedics. It is also the leader in joint replacement segment with a broad product portfolio of hip and knee replacement and extremities. Likewise, Straumann dominated the dental segment in 2015, primarily due to a large number of successful product launches in dental implants market, which helped it to grow at a faster rate and gain a lead in the industry. As of 2015, the neurostimulator market was dominated by three major players, namely, Medtronic, St Jude Medical and Boston Scientific.
Technological advancements — such as the VLSI-based chip architecture of AdvaStim’s ASICore technology, which provides multi-channel switching and electrode programming capabilities — led the market to grow at a steady rate. These innovations are enabling the companies to develop new and better medical implants providing advance healthcare solutions in unmet clinical areas.
The medical implants market has become consolidated due to a large number of strategic acquisitions in the industry. These acquisitions enabled the key players to rapidly expand their business operations of the respective segments in implantable devices industry.
Top Winning Strategies: Percentage Distribution (2014-2016)
Among the analysed strategies, product approvals were the key strategy adopted by the key players in the medical implants market. For instance, in April 2016, Medtronic received the US FDA approval for The Micra TPS, which is the world’s smallest pacemaker; it also obtained CE Mark approval for this product in April 2015. Prior to this, Zimmer Biomet launched the hip replacement and knee implant systems, enabling the company to expand its implant and musculoskeletal treatment product portfolio.
Furthermore, the companies have also adopted the inorganic strategy of acquisitions and mergers to increase their market share and sustain their leading positions in the industry. For instance, in October 2015 St Jude Medical acquired Thoratec, a medical devices company based in the United States. This acquisition helped St Jude Medical to increase its market share in the ventricular assist devices (VADs) segment, thus offering innovative technologies for heart failure treatment. As a result, the company leads the overall VADs market. Moreover, in April 2016, Abbott Laboratories made an announcement to acquire St Jude Medical. This acquisition will enable Abbott to build its leading position in the high-growth cardiovascular segments (such as structural heart and heart failure and atrial fibrillation) as well as in the neuromodulation market.
Following are some other strategic developments in the medical implants industry:
February 2016: Biotronik received the CE Mark approval for a series of ICDs and CRT-Ds with MRI AutoDetect and ProMRI technology. It enhanced its cardiac device business segment. Along with this, Boston Scientific received the FDA approval for quadripolar left ventricular (LV) leads. With this approval, Boston Scientific began a global trial to expand MRI labelling in Asia and the US. In addition, the company will also offer a full CRT system including leads in the US market.
October 2015: St Jude Medical acquired Thoratec, a medical devices company based in the US. This acquisition has enabled St Jude Medical to produce mechanical circulatory support (MCS) technology used for treating advanced heart failure. This acquisition strengthened its product offerings for heart failure treatment technologies and the company has now become a leader in the ventricular assist devices market.
In addition, St Jude Medical also received the CE mark approval for HeartMate 3 Left Ventricular Assist System (LVAS) for advanced heart failure patients. This approval helped the company to enhance its VAD portfolio in Europe.
March 2015: Sorin (Italy) signed a merger agreement with Cyberonics (US), which established LivaNova as the holding company of the combined business of both Sorin and Cyberonics. This merger helped in the expansion of business into two new segments namely cardiac rhythm management and cardiac surgery, which has led to an increase in sales of LivaNova.
The author, Snehal Chougule, is a keynote senior consultant on digital marketing at Allied Market Research. She has been recognized for developing a robust social network strategy for the company. Chougule has written several whitepapers, case studies, and articles. She is a visiting faculty member at various educational institutions and has expertise in life sciences and medical devices.
A new report published by Allied Market Research titled, World Congestive Heart Failure (CHF) Treatment Devices Market – Opportunities and Forecasts, 2015 -2022, projects that the world CHF treatment devices market would reach $14.8 billion by 2022, at a CAGR of 5.5% from 2016 to 2022. Implantable cardioverter-defibrillator (ICDs) segment is expected to dominate the world CHF treatment devices market throughout the forecast period. North America is projected to continue its lead in terms of revenue, accounting for more than two-fifths share of the world CHF treatment devices.
To know more about the report at: https://www.alliedmarketresearch.com/congestive-heart-failure-treatment-devices-market
The major factors boosting the market growth include the growing incidence of heart failures, technological advancements in CHF treatment devices, and increasing adoption rates for these devices. In addition, rising incidence of diabetes, atherosclerosis, strokes, hypertension, and others due to faulty lifestyle habits such as unhealthy dietary habits, lack of physical activity, and smoking, among others are the leading causes of congestive heart failure. Rising geriatric population base is expected to fuel the prevalence of congestive heart failures thereby augmenting the market growth. Presence of huge unmet medical needs and rising emphasis on early intervention and primary prevention of heart failures are also anticipated to drive the demand for these devices. However, high cost of these devices and unfavorable reimbursement scenario in the emerging countries are some of the factors that restrict the market growth.
The Implantable Cardioverter Defibrillators (ICDs) segment would maintain its lead in the market throughout the analysis period, primarily because of the increasing number of patients with faster-than-normal rhythm as the mean age of the global population is shifting towards older age groups. Ventricular assist devices (VADs) has emerged as the fastest growing segment, with a CAGR of 11.9%. Increasing focus on the development of advanced VDAs and miniaturization of VADs are the major factors responsible for the growth of this market.
Key findings of the study:
- In 2015, ICDs accounted for almost one-third of the overall market revenue, and is projected to grow at a CAGR of 4.8% during the forecast period.
- The VADs segment is likely to grow at a remarkable CAGR of 11.9%, owing to the innovation and miniaturization of devices.
- North America accounted for over 40% share of the world CHF treatment devices market in 2015.
- The U.S. is projected to maintain its lead in the world CHF treatment devices market until 2022.
- China and Japan are the major shareholders in the Asia-Pacific region, jointly accounting for almost half of share in the Asia-Pacific market.
Geographically, North America accounted for the majority of the share in the world CHF treatment devices market in 2015, and is expected to maintain this lead throughout the forecast period. This was mainly attributed to the increasing incidence of heart failures, presence of highly sophisticated healthcare infrastructure, and adoption of advanced CHF treatment devices in the North American countries. However, Asia-Pacific is expected to be the fastest growing region throughout the analysis period, owing to ample growth opportunities in terms of unmet medical needs for the treatment of cardiac disorders in these regions.
The key players profiled include Abiomed, Inc., Berlin Heart GmbH, Biotronik SE & Co. KG, Boston Scientific Corporation, HeartWare International, Inc., Jarvik Heart, Inc., LivaNova PLC, Medtronic plc, ReliantHeart Inc., and St. Jude Medical, Inc.
Biopsy is the surgical removal of tissue from an organ to determine the presence or extent of a disease, mostly cancerous and inflammatory conditions.
In an official press release on June 1, 2016, the U.S. Food and Drug Authority (FDA) sanctioned regulatory approval to the first ever blood-based assay, cobas EGFR mutation Test v2, for the drug Tarceva. EGFR, or epidermal growth factor receptor, occurs in two out of 10 cases of non-small cell lung cancer (NSCLC). DNA from the tumor cells, pass into vascular system and into the blood, enabling blood samples to be used for effective detection of any signs of mutation.
“Approvals of liquid biopsy tests, make it possible to deliver highly individualized health care for patients,” said Alberto Gutierrez, Ph.D., director of the Office of In Vitro Diagnostics and Radiological Health in the FDA’s Center for Devices and Radiological Health. “Liquid biopsies also have the potential to allow physicians to identify patients whose tumors have specific mutations in the least invasive way possible.”
To view the report visit at: https://www.alliedmarketresearch.com/biopsy-devices-market
Manufactured by Roche Molecular Systems in Pleasanton, California, cobas EGFR Mutation Test v2 biopsy device, specifically determines exon 19 deletion or exon 21 (L858R) substitution mutations. This helps in differentiating those cases, which would benefit from Tarceva. In case, any mutation is not registered only then would a tumor biopsy be necessary.
On June 6, 2016, came the reported success of Next-2 trial, a comprehensive liquid biopsy tool, during first set of clinical trials by Guardant Health and Samsung Medical Center. A batch of 200 patients, diagnosed with advanced stages of cancer, were included as subjects for the trial. The aim was to validate the use of NEXT-2 liquid biopsy “as the sole diagnostic tool” to assist oncologists in establishing the efficacy of therapeutic drugs for different types of cancer. The resultant outcome of the study, was fairly satisfying for the researchers in improving net efficiency of this biopsy technique. In addition, it helped generate substantial response rates for some types of cancer, 88% in lung cancer and 60% in gastric cancer.
A group of investigators from Johns Hopkins Kimmel Cancer Center and the University of Melbourne ventured to implement liquid biopsy for estimating recurrence rates of colon cancer. A small batch of early-stage colon cancer patients were studied during their research. They released their findings during early July, 2016 suggesting its success. They had innovated a basic test to assist clinical experts plan whether or not a patient diagnosed with early stages would require further therapies for stage II. This is essential with regard to the fact that that stage II tumors do influence, but not infect other organs in vicinity. Therefore, there exists no proof of benefit from chemotherapy post-surgery. The liquid biopsy test discussed in their study, proved its potential to define extreme-risk scenario. Later, it was easier to comprehend the degree of positive response generated in them, once supplementary treatments were given.
“When such a generic test is developed, it could still catch more than 90% of colorectal cancers, and it would eliminate the need to retrieve and test individual tumor samples, thus saving time, effort, and money,” added Peter Gibbs, M.D., a Ludwig investigator at WEHI who co-led the study.
“There is mounting evidence that ctDNA [circulating tumor DNA] is a viable approach for earlier detection of cancer recurrence, and more research is underway to refine the technology, improve its sensitivity and determine the best testing intervals,” concluded co-author Kenneth Kinzler, Ph.D., co-director of the Ludwig Center at the Johns Hopkins Kimmel Cancer Center.
Non-invasive, is the keyword, when it comes to the popularity of liquid biopsy techniques. A cancer-struck patient, too sick for painful surgical extraction of tumor cells, finds comparative relief in those small needle pricks. Besides that, the researchers have the benefit of a more complex genetic profile, rather than just the tumor cells.
The precision medicine segment finds exciting applications for minimal, or non-invasive technique of isolating tumor DNA from bio fluids for liquid biopsy. Previously, even with the recognition of prominent molecular signatures, building up patient cohorts with similar profile using biomarkers as the base, failed in practical scenarios. It was combination of targeted proteomics and computational biology that helped recognize significant signatures in prostate cancer. With advanced devices that have been trained through rigorous datasets it becomes easier to build predictive models. As far as the research in that segment goes, computer-assisted proteomics would eventually lead to the sighting of high-accuracy biomarkers in body fluids. The world biopsy market expects high projections of market shares to the account of liquid biopsy segment given the current investigative trends.
Find all reports related to medical devices at: https://www.alliedmarketresearch.com/life-sciences/medical-devices-market-report
According to a new report published by Allied Market Research, titled, “Powder Coatings Market – Opportunities and Forecasts, 2014–2022,” the powder coatings market is expected to generate $12,332 million by 2022. Powder coatings in appliances application segment occupied the major volume share in 2015 and is expected to maintain its lead throughout the analysis period.
The demand for powder coatings has increased owing to growing technological advancements and increasing demand from applications, namely, architectural; appliances; automotive; furniture; agriculture, construction, and earthmoving equipment (ACE); general industrial; and others. This trend is expected to continue as it is a volatile organic compound (VOC) and solvent-free. Strict environmental regulations also boost the growth of this market. The market has witnessed moderate growth during the past few years and is expected to grow at a CAGR of 6.3%, in terms of volume, during the analysis period.
Significant drivers of the market include increasing adoption of powder coatings over liquid coatings, supporting environmental regulations, increasing demand for appliances, booming construction industry, and rapid economic growth in emerging countries. However, difficulty in the application of thin coats is expected to impede this growth.
To know more about the report, visit the website at https://www.alliedmarketresearch.com/powder-coatings-market
In the year 2015, thermoset powder coatings segment occupied a dominating position as it provides superior finish with excellent durability that reduces the maintenance and prolongs the shelf life of the coated products. Moreover, stringent regulations have led to increased penetration of powder coatings over liquid coatings. Powder coating overspray can be recycled and reused, which means 100% coating material can be utilized. Powder coatings in appliances application segment occupied around one-fourth of the total market in 2015 and is expected to continue the same trend throughout the forecast period.
Electrostatic spray is the most adopted coating technique as it enables coating of intricate shapes and does not require preheating of components. This segment is expected to continue its dominance throughout the forecast period.
Key Findings of the Powder Coatings Market
- The appliances application segment occupied the highest share in 2015 and is expected to grow with a CAGR of 6.7%, in terms of volume.
- Electrostatic spray technique was the dominant segment in 2015 and is anticipated to maintain its lead in the powder coatings market.
- The thermoset segment is expected to expand with the highest CAGR of 6.4%, in terms of volume.
- China is the leading consumer of powder coatings in the Asia-Pacific region followed by India.
- The furniture application is projected to be the fastest growing segment.
Asia-Pacific accounted for more than half of the total powder coatings market in 2015 and is expected to maintain its lead position throughout the forecast period. This is attributable to the increasing domestic production of automotive, appliances, and growing construction industry. In Asia-Pacific, China is the fastest growing country for the consumption of powder coatings and is expected to continue this dominance during the forecast period in terms of both, volume and revenue.
The prominent players profiled include BASF SE, Akzo Nobel N.V., Kansai Nerolac Paints Limited, Axalta Coating Systems, PPG Industries, Berger Paints, IFS Coatings, Tiger Coatings, The Valspar Corporation, and Sherwin Williams.
Find all reports related to Materials & Chemicals Industry at: https://www.alliedmarketresearch.com/materials-&-chemicals-market-report
Growing adoption of construction chemicals with best practices across the world, to meet consumer international standards, is expected to increase the current market penetration levels.
According to a new report published by Allied Market Research, titled, “Construction Chemicals Market – Global Opportunity Analysis and Industry Forecast, 2014 – 2022“, the market is poised to reach $40,154 million by 2022, from $27,162 million in 2015, growing with a CAGR of 5.6% from 2016 to 2022. The concrete admixtures segment leads the construction chemicals market with more than one-third of the market share during the forecast period.
Construction chemicals are chemical compounds that optimize the performance of concrete and increase the life of end products. These additions provide further value for end users by reducing labor cost and minimizing wastage. The key elements that drive the construction chemicals market growth include rise in construction industry, increase in urbanization, and growth in conformity with latest manufacturing standards. However, change in regulatory environment and low consumer awareness inhibit the market growth.
Concrete admixtures and water proofing & roofing chemical segments together dominated the construction chemicals market in 2015, accounting around two-thirds of the market share collectively. Concrete admixtures segment is expected to grow with a high CAGR of 9.9%, in volume terms, owing to the increased compressive strength and enhanced workability, so as to provide higher moving and positioning time. Residential and infrastructure end-user segments collectively accounted for three-fifths of the market share, in terms of volume, in 2015. Infrastructure segment is estimated to grow at the fastest rate with a CAGR of 7.7% during the forecast period.
View more details of the report @ https://www.alliedmarketresearch.com/construction-chemicals-market
Key Findings of Construction Chemicals Market
- Infrastructure segment is projected to grow at the fastest rate with a CAGR of 9.7% (volume terms).
- Flooring, a type of construction chemicals, is projected to grow with a CAGR of 9.6% (volume terms) during the forecast period.
- Residential segment accounted for around half of the market share, in terms of value, in 2015.
- LAMEA is projected to occupy the highest market value, registering a CAGR of 5.8%.
- Asia-Pacific amounted for more than two-fifths of the market share, by volume, in 2015, growing at a CAGR of 10.2%.
The Asia-Pacific and LAMEA construction chemicals market is expected to offer lucrative growth opportunities, during the forecast period, with CAGRs of 5.8% and 6.1%, respectively. This is due to increase in economic development, expansion in the construction industry, and rise in the need for better infrastructure. The key players profiled in the world construction chemicals market include BASF SE, Arkema SA, Ashland Inc., Fosroc International Limited, Mapie S.p.A, Pidilite Industries, RPM International Inc., Sika AG, The Dow Chemical Company, and W.R. Grace & Company.